MedTrace Logo

Bioavailability Study of Tramadol/APAP Tablets Under Fed Conditions

NCT00652821 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2017-09-26

No results posted yet for this study

Summary

To compare the relative bioavailability of Kali and Ortho-McNeil's products

Conditions

  • To Determine Bioequivalence Under Fed Conditions

Interventions

DRUG

Tramadol/ APAP

Tablets 37.5mg /325mg

DRUG

Ultracet

Tablets, 37.5mg/325mg

Sponsors & Collaborators

  • AAI Clinic

    collaborator OTHER

  • Par Pharmaceutical, Inc.

    lead INDUSTRY

Principal Investigators

  • Ralph Scallion · AAI Clinic

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-05-31
Primary Completion
2002-08-31
Completion
2002-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00652821 on ClinicalTrials.gov